Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Jefferies

Climate change, scarcity chip away at degrowth taboo

Degrowth - the idea that a finite planet cannot sustain ever-increasing consumption - is about the closest you can get to a heresy in economics, where growth is widely held as the best route to prosperity.

Reuters

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022

Upgrades

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022

Upgrades

Benzinga

Jefferies Maintains Hold Rating for Douglas Emmett: Here's What You Need To Know

Jefferies has decided to maintain its Hold rating of Douglas Emmett (NYSE:DEI) and lower its price target from $31.00 to $24.00. Shares of Douglas Emmett are trading down 1.04% over the last 24 hours, at $22.32 per share. A move to $24.00 would account for a 7.5% increase from the…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Xenon Pharmaceuticals Shares Drop On Proposed Public Offering

Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced an underwritten public offering of its common shares. Underwriters of the offering will be granted an option for a period of 30 days to purchase an additional 15% of common shares at the public offering price. Jefferies, J.P. Morgan, SVB Securities, and Stifel are acting as joint…

Benzinga

Microsoft Whale Trades For June 17

Someone with a lot of money to spend has taken a bearish stance on Microsoft (NASDAQ:MSFT). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Jefferies Maintains Buy Rating for Outbrain: Here's What You Need To Know

Jefferies has decided to maintain its Buy rating of Outbrain (NASDAQ:OB) and lower its price target from $9.00 to $8.00. Shares of Outbrain are trading down 14.48% over the last 24 hours, at $4.75 per share. A move to $8.00 would account for a 68.24% increase from the current share…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022

Upgrades

Benzinga

Tapestry — Owner Of Fashion Brand Coach — Is A "Structural Pandemic Winner," Jefferies Says In Upgrade: What Else Impressed This Analyst?

Tapestry Inc (NYSE: TPR) has been through a culture change focusing on data-driven results, which should continue to drive progress, according to Jefferies.

Benzinga

Microsoft Whale Trades Spotted

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2022

Upgrades

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

10 Biggest Price Target Changes For Wednesday

Jefferies raised Tapestry, Inc. (NYSE: TPR) price target from $30 to $45. Tapestry shares rose 2.2% to close at $31.60 on Tuesday.

Benzinga

Jefferies Maintains Buy Rating for SVB Finl Gr: Here's What You Need To Know

Jefferies has decided to maintain its Buy rating of SVB Finl Gr (NASDAQ:SIVB) and lower its price target from $692.00 to $534.00. Shares of SVB Finl Gr are trading down 7.14% over the last 24 hours, at $411.27 per share. A move to $534.00 would account for a 29.84% increase…

Reuters

Age to buy cigarettes in England should rise every year, review says

The legal age of sale for cigarettes in England should be raised by one year every year until eventually no one can buy tobacco products, a government-commissioned review said on Thursday.

Benzinga

79 Biggest Movers From Yesterday

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

38 Stocks Moving In Tuesday's Mid-Day Session

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) gained 70% to $0.4900 after the company entered a sponsored research agreement under which in vivo preclinical data will be generated from Kiromic's Gamma Delta T cell allogeneic therapies.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

Upgrades

Benzinga

What's Going On With Datadog Stock Today?

Datadog Inc (NASDAQ: DDOG) shares are trading higher Thursday amid overall market strength in the technology and software sector.

Benzinga

Tesla Stock Gets Another Price Target Cut — This Time From Jefferies

Tesla, Inc.

Benzinga

4 Investors Make The Case For Microsoft Stock After Analyst Slashes Price Target

Microsoft Corp (NASDAQ: MSFT) was featured as the call of the day Monday on CNBC's "Fast Money Halftime Report."

Benzinga

Jefferies Maintains Hold Rating for Ceridian HCM Holding: Here's What You Need To Know

Jefferies has decided to maintain its Hold rating of Ceridian HCM Holding (NYSE:CDAY) and lower its price target from $65.00 to $56.00. Shares of Ceridian HCM Holding are trading up 0.57% over the last 24 hours, at $56.92 per share.

Benzinga

56 Stocks Moving In Friday's Mid-Day Session

Gainers Veru Inc. (NASDAQ: VERU) shares jumped 62.5% to $14.67 after the company reported quarterly results on Thursday. Jefferies maintained Veru with a Buy and raised the price target from $33 to $55.

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.